Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1983 Dec;80(23):7318–7322. doi: 10.1073/pnas.80.23.7318

Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.

R F Ebert, W R Bell
PMCID: PMC390046  PMID: 6580646

Abstract

A congenital hypodysfibrinogenemia, fibrinogen Baltimore II, was found in a young asymptomatic Caucasian female. Prothrombin, partial thromboplastin, and euglobulin lysis times were normal, as were platelet function and coagulation factor assays. Subnormal plasma fibrinogen levels were found using chronometric, rate-independent, and immunologic assay methods. Kinetic analysis of fibrinopeptide release revealed a delay in the thrombin-catalyzed release of fibrinopeptide B from the abnormal protein. Proteolysis of fibrinopeptide A by thrombin or Arvin, fibrin monomer polymerization, and fibrin polymer ligation occurred at normal rates. Catabolism of radiolabeled autologous and homologous fibrinogen was also normal, but the fibrinogen synthetic rate was less than half the normal value. Comparison of the coagulation characteristics of fibrinogen Baltimore II with those of other abnormal fibrinogens indicates that it represents a unique example of hypodysfibrinogenemia.

Full text

PDF
7318

Images in this article

7321Image
on p.7321

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Mondhiry H., Bilezikian S. B., Nossel H. L. Fibrinogen ""New York"--an abnormal fibrinogen associated with thromboembolism: functional evaluation. Blood. 1975 May;45(5):607–619. [PubMed] [Google Scholar]
  2. Beck E. A., Charache P., Jackson D. P. A new inherited coagulation disorder caused by an abnormal fibrinogen ('fibrinogen Baltimore'). Nature. 1965 Oct 9;208(5006):143–145. doi: 10.1038/208143a0. [DOI] [PubMed] [Google Scholar]
  3. Blomback B., Blomback M. Molecular defects and variants of fibrinogen. Nouv Rev Fr Hematol. 1970 Sep-Oct;10(5):671–678. [PubMed] [Google Scholar]
  4. Blombäck M., Blombäck B., Mammen E. F., Prasad A. S. Fibrinogen Detroit--a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature. 1968 Apr 13;218(5137):134–137. doi: 10.1038/218134a0. [DOI] [PubMed] [Google Scholar]
  5. Branson H. E., Schmer G., Dillard D. H. Fibrinogen Seattle: a qualitatively abnormal fibrinogen in a patient with tetralogy of Fallot. Am J Clin Pathol. 1977 Mar;67(3):236–240. doi: 10.1093/ajcp/67.3.236. [DOI] [PubMed] [Google Scholar]
  6. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  7. Collen D., Tytgat G. N., Claeys H., Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol. 1972 Jun;22(6):681–700. doi: 10.1111/j.1365-2141.1972.tb05715.x. [DOI] [PubMed] [Google Scholar]
  8. Fenton J. W., 2nd, Fasco M. J., Stackrow A. B. Human thrombins. Production, evaluation, and properties of alpha-thrombin. J Biol Chem. 1977 Jun 10;252(11):3587–3598. [PubMed] [Google Scholar]
  9. Flute P. T. Disorders of plasma fibrinogen synthesis. Br Med Bull. 1977 Sep;33(3):253–259. doi: 10.1093/oxfordjournals.bmb.a071444. [DOI] [PubMed] [Google Scholar]
  10. Gralnick H. R., Coller B. S., Fratantoni J. C., Martinez J. Fibrinogen bethesda III: a hypodysfibrinogenemia. Blood. 1979 Jan;53(1):28–46. [PubMed] [Google Scholar]
  11. Gralnick H. R., Givelber H. M., Finlayson J. S. A new congenital abnormality of human fibrinogen. Fibrinogen Bethesda II. Thromb Diath Haemorrh. 1973 Jun 28;29(3):562–571. [PubMed] [Google Scholar]
  12. Gralnick H. R., Givelber H. M., Shainoff J. R., Finlayson J. S. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest. 1971 Sep;50(9):1819–1830. doi: 10.1172/JCI106673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. HARDISTY R. M., MACPHERSON J. C. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh. 1962 May 15;7:215–228. [PubMed] [Google Scholar]
  14. Higgins D. L., Shafer J. A. Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue. J Biol Chem. 1981 Dec 10;256(23):12013–12017. [PubMed] [Google Scholar]
  15. Krohn K., Sherman L., Welch M. Studies of radioiodinated fibrinogen. I. Physicochemical properties of the ICl, chloramine-T, and electrolytic reaction products. Biochim Biophys Acta. 1972 Dec 28;285(2):404–413. doi: 10.1016/0005-2795(72)90327-3. [DOI] [PubMed] [Google Scholar]
  16. Kuyas C., Haeberli A., Straub P. W. A subfraction of human fibrinogen with high sialic acid content and elongated gamma chains. J Biol Chem. 1982 Feb 10;257(3):1107–1109. [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  19. MATTHEWS C. M. The theory of tracer experiments with 131I-labelled plasma proteins. Phys Med Biol. 1957 Jul;2(1):36–53. doi: 10.1088/0031-9155/2/1/305. [DOI] [PubMed] [Google Scholar]
  20. Mammen E. F., Prasad A. S., Barnhart M. I., Au C. C. Congenital dysfibrinogenemia: fibrinogen Detroit. J Clin Invest. 1969 Feb;48(2):235–249. doi: 10.1172/JCI105980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Marder V. J. The functional defects of hereditary dysfibrinogens. Thromb Haemost. 1976 Aug 31;36(1):1–8. [PubMed] [Google Scholar]
  22. Martinelli R. A., Scheraga H. A. Assay of bovine fibrinopeptides by high performance liquid chromatography. Anal Biochem. 1979 Jul 1;96(1):246–249. doi: 10.1016/0003-2697(79)90579-7. [DOI] [PubMed] [Google Scholar]
  23. Martinez J., Holburn R. R., Shapiro S. S., Erslev A. J. Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism. J Clin Invest. 1974 Feb;53(2):600–611. doi: 10.1172/JCI107595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McDonagh R. P., Carrell N. A., Roberts H. R., Blatt P. M., McDonagh J. Fibrinogen Chapel Hill: hypodysfibrinogenemia with a tertiary polymerization defect. Am J Hematol. 1980;9(1):23–38. doi: 10.1002/ajh.2830090104. [DOI] [PubMed] [Google Scholar]
  25. McFarlane A. S. IN VIVO BEHAVIOR OF I-FIBRINOGEN. J Clin Invest. 1963 Mar;42(3):346–361. doi: 10.1172/JCI104721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Merskey C., Lalezari P., Johnson A. J. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med. 1969 Jul;131(3):871–875. doi: 10.3181/00379727-131-33998. [DOI] [PubMed] [Google Scholar]
  27. NYE S. W., GRAHAM J. B., BRINKHOUS K. M. The partial thromboplastin time as a screening test for the detection of latent bleeders. Am J Med Sci. 1962 Mar;243:279–287. doi: 10.1097/00000441-196203000-00002. [DOI] [PubMed] [Google Scholar]
  28. OUCHTERLONY O. Diffusion-in-gel methods for immunological analysis. II. Prog Allergy. 1962;6:30–154. doi: 10.1159/000313795. [DOI] [PubMed] [Google Scholar]
  29. QUICK A. J., HUSSEY C. V., GEPPERT M. PROTHROMBIN: ANALYTICAL AND CLINICAL ASPECTS. COMPARISON OF THE ONE- AND TWO-STAGE METHODS. Am J Med Sci. 1963 Nov;246:517–526. [PubMed] [Google Scholar]
  30. RATNOFF O. D., MENZIE C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med. 1951 Feb;37(2):316–320. [PubMed] [Google Scholar]
  31. Ratnoff O. D., Forman W. B. Criteria for the differentiation of dysfibrinogenemic states. Semin Hematol. 1976 Apr;13(2):141–157. [PubMed] [Google Scholar]
  32. Reeve J., Pussell B., Gibbs G. P., Peters D. K. Interpretation of tracer studies on plasma protein turnover: comparison of methods and optimization of techniques. Clin Sci (Lond) 1982 Aug;63(2):175–185. doi: 10.1042/cs0630175. [DOI] [PubMed] [Google Scholar]
  33. Shainoff J. R., Dardik B. N. Fibrinopeptide B and aggregation of fibrinogen. Science. 1979 Apr 13;204(4389):200–202. doi: 10.1126/science.155308. [DOI] [PubMed] [Google Scholar]
  34. Tyler H. M. A comparative study of the solvents commonly used to detect fibrin stabilisation. Thromb Diath Haemorrh. 1966 Jul 31;16(1):61–68. [PubMed] [Google Scholar]
  35. VON KAULLA K. N., SCHULTZ R. L. Methods for the evaluation of human fibrinolysis; studies with two combined technics. Am J Clin Pathol. 1958 Feb;29(2):104–112. doi: 10.1093/ajcp/29.2.104. [DOI] [PubMed] [Google Scholar]
  36. Verhaeghe R., Verstraete M., Vermylen J., Vermylen C. Fibrinogen 'Leuven', another genetic variant. Br J Haematol. 1974 Mar;26(3):421–433. doi: 10.1111/j.1365-2141.1974.tb00483.x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES